Drawing for GRYPHIRA

USPTO serial 79310429

GRYPHIRA

Reviewed by CopyMark Law Group

Reg. 6541782Status 404
Filing date
Status date
Registration date
Nov 2, 2021
Examiner
MCDOWELL, MATTHEW J
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GRYPHIRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 18, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Aug 18, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
May 15, 2022FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 25, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 25, 2022FIMPFINAL DISPOSITION PROCESSED—
Feb 2, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 2, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 29, 2021GPNXNOTIFICATION PROCESSED BY IB—
Aug 17, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 17, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 4, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 4, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 28, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 24, 2021RFNTREFUSAL PROCESSED BY IB—
Jul 12, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 12, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 12, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 12, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 9, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 9, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 9, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 9, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 9, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 9, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 26, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 25, 2021RFRRREFUSAL PROCESSED BY MPU—
Jun 18, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 17, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 6, 2021CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Jun 2, 2021DOCKASSIGNED TO EXAMINER—
May 27, 2021DOCKASSIGNED TO EXAMINER—
May 18, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
May 12, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 11, 2021LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
May 8, 2021SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance